CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 62 enrolled
Drug / intervention
Lactobacillus casei strain Shirotadietary
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03100851
NCT03100851Phase 3Completed
CompareCT.gov

Effect of Fermented Milk Containing Lactobacillus Casei Strain Shirota on Chinese People With Constipation

China Agricultural University·interventional·Posted Apr 4, 2017·Updated Jun 29, 2017

In Brief

A Phase 3 clinical trial evaluating Lactobacillus casei strain Shirota for Constipation. Completed, enrolled 62 participants.

Detailed Summary

Constipation is a prevalent intestinal disorder. Lactobacillus casei strain Shirota (LcS) shows potential effect on alleviating constipation. This study evaluated the impact of fermented milk containing LcS on stool consistency and frequency. The stool short chain fatty acid and gut microbiota were also assessed.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsConstipation
Countries--
Collaborators--

Timeline

Phase 3CompletedFinished
20162017201820192020202120222023202420252026
First PostedApr 4, 2017
Enrollment StartAug 2, 2015
Primary CompletionSep 26, 2016
Study CompletionMar 17, 2017
TodayJul 2, 2026
Enrollment to primary: 1.2 yearsPosted 9.2 years ago

Interventions

Lactobacillus casei strain Shirotadietary

a bottle of 100 mililiter probiotic dairy beverage containing 10\^8 CFU Lactobacillus casei strain Shirota every day after lunch.